OpenAlex
PricingAboutJobs
Log inGet started
Work

Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China

HTML

Year: 2022
Type: article
Source: Clinical Drug Investigation
DOI: 10.1007/s40261-022-01197-9
Authors: Qingqing Chai, Haini Wen, Yitian Lang, Lingyu Zhang, Yan Song, Xiaoyan Liu
Institutions: Shanghai Jiao Tong University, Shanghai Ninth People's Hospital, Shanghai Chest Hospital, Renji Hospital
Language: English

Topic: Biosimilars and Bioanalytical Methods
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Keywords: trastuzumab biosimilar, HER2-positive breast cancer, budget impact, biosimilar switching, payer perspective, cost reduction, volume-based procurement, drug price regulation, access to targeted therapy, China
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W4296139527
FWCI: 0.599
Cites: 40
Cited by: 10
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security